Illumina announced that the Centers for Medicare & Medicaid Services has approved reimbursement for its FDA‑approved TruSight Oncology Comprehensive (TSO Comprehensive) test, effective January 1, 2026. The decision assigns a reimbursement rate of $2,989.55 per test under the Clinical Laboratory Fee Schedule using the Proprietary Laboratory Analysis code 0543U, creating a predictable payment pathway for Medicare beneficiaries.
The approval removes a significant barrier to adoption, allowing laboratories of all sizes to bring the test in‑house and deliver actionable genomic insights closer to the point of care. By expanding access to comprehensive genomic profiling, Illumina is expected to increase test volume and strengthen its clinical consumables revenue, which accounted for roughly 60% of the company’s sequencing consumables income in 2025. The new reimbursement is a key driver of the shift toward a higher‑margin clinical mix that Illumina has been pursuing.
In the most recent earnings data, Illumina’s Q4 2024 revenue was $1.1 billion, up 1% from Q4 2023, while preliminary full‑year 2025 revenue was flat at $4.34 billion versus $4.28 billion in 2024. Gross margin rose in 2024, driven by operational excellence initiatives and a more favorable revenue mix toward sequencing consumables. The CMS decision is expected to accelerate the uptake of TSO Comprehensive across academic, community, and commercial laboratories, reinforcing Illumina’s leadership in precision oncology diagnostics.
John Fox, MD, senior director of Market Access and Government Affairs, said the decision “helps remove barriers that have limited adoption of comprehensive genomic profiling for patients, empowering more healthcare providers to deliver precision oncology insights that will improve outcomes.” The reimbursement is a tangible tailwind that supports Illumina’s strategy to grow high‑margin, high‑volume clinical sequencing while offsetting headwinds in the research market.
On the day of the announcement, Illumina’s stock traded down 3.24% on Nasdaq. The decline was attributed to the company’s decision not to provide guidance for the upcoming year at the J.P. Morgan Healthcare Conference, coupled with uncertainties in academic markets and China. Despite the positive regulatory milestone, investors focused on the lack of forward guidance and broader market uncertainties.
The CMS reimbursement is a material development that could shift Illumina’s revenue mix toward higher‑margin clinical consumables, strengthen its precision oncology diagnostics portfolio, and provide a counterbalance to challenges in the research segment. The decision is expected to accelerate test volume and reinforce Illumina’s competitive position in the genomics market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.